"
Team:EPF-Lausanne/Safety
From 2011.igem.org
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | {{:Team:EPF-Lausanne/Templates/Header|title= | + | {{:Team:EPF-Lausanne/Templates/Header|title=Safety}} |
| - | |||
The 2011 EPFL iGEM team has taken two approaches to its engineering work on transcription factors: one is in vivo and the other is in vitro. Neither presents any form of unusual safety risk. Nevertheless, we should highlight a few aspects of the work that present some risk to the public and to the researcher. | The 2011 EPFL iGEM team has taken two approaches to its engineering work on transcription factors: one is in vivo and the other is in vitro. Neither presents any form of unusual safety risk. Nevertheless, we should highlight a few aspects of the work that present some risk to the public and to the researcher. | ||
Revision as of 12:22, 27 June 2011
Safety
The 2011 EPFL iGEM team has taken two approaches to its engineering work on transcription factors: one is in vivo and the other is in vitro. Neither presents any form of unusual safety risk. Nevertheless, we should highlight a few aspects of the work that present some risk to the public and to the researcher.
§ The in vivo manipulation of E. coli using various antibiotics, like ampicillin and kanamycin, always presents a minimal amount of risk to those who would be exposed to a resistant strain.
